Result of Oversubscribed Retail Offer

596/2014, AS INCORPORATED INTO UK LAW BY THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Result of Oversubscribed Retail Offer

Proteome Sciences (AIM: PRM) is pleased to announce that the Retail Offer launched on 26 January 2026 has successfully completed and closed today at 12.00 p.m.

The Retail Offer was significantly oversubscribed. Accordingly, the Company has elected to increase the scale of the Retail Offer and has raised in aggregate £132,000 through the issuance of 7,542,856 Retail Offer Shares at an issue price of 1.75 pence per Retail Offer Share.

The Retail Offer is conditional on Admission, which is expected to take place at 8:00 a.m. on 29 January 2026.

In total, the Issue has raised gross proceeds of £972,000 for the Company.

The proceeds of the Retail Offer, together with the proceeds of the Fundraise announced on 26 January 2026, will enable the Company to fund the following workstreams:

o Increasing Tandem Mass Tag ("TMT") tags plexing rate from 32X to 96X;

o Launching an innovative new range of DXT isotopic plex tags;

o Introducing novel 'Solvent Shift' chemoproteomic workflows;

o Concluding a DXT licence;

o Expanding staff and mass spectrometry ("MS") capacity in San Diego to meet demand; and

o Additional working capital.

Proteome Sciences Chief Scientific Officer, Dr. Ian Pike, said:

"The Proteome Sciences team and I greatly appreciate the level of interest shown in the Fundraise by both new and existing institutional investors and a new cohort of retail investors who have participated in the oversubscribed Retail Offer.

Now the Fundraise has successfully completed, we look forward to providing our shareholders with further updates regarding our key workstreams, specifically those relating to the further development of our TMT tags, along with the future launch and conclusion of commercial licensing of the new range of DXT isotopic plex tags. We also look forward to accelerating our novel 'Solvent Shift' chemoproteomic workflows and expanding both our team and our MS capacity at our San Diego facility."

Director and Related Party Shareholdings

Following Admission, the percentage holdings of the Related Parties who participated in the Fundraise are set out in the table below:

Admission to trading on AIM and Total Voting Rights

Application has been made to the London Stock Exchange for the Admission of the 7,542,856 Retail Offer Shares. Admission is expected to take place and dealings in the Retail Offer Shares are expected to commence at 8.00 a.m. on 29 January 2026, at which time it is also expected that the Retail Offer Shares will be enabled for settlement in CREST.

Admission of the Fundraise Shares is also expected to take place at 8.00 a.m. on 29 January 2026. Upon Admission of the Fundraise Shares and Retail Offer Shares, the Company's issued share capital will consist of 350,724,912 Ordinary Shares. Each Ordinary Share has one voting right and no Ordinary Shares are held in treasury. From Admission, this figure may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The Retail Offer Shares to be issued pursuant to the Retail Offer will rank pari passu with the Ordinary Shares.

Note

Defined terms used in this announcement shall have the same meaning as in the '£840,000 Fundraise and Retail Offer' and 'Retail Offer to raise up to £60,000' announcements dated 26 January 2026 unless otherwise defined herein.

UK Product Governance Requirements

EU Product Governance Requirements